Delivering for you, so you can deliver a difference
Every day we try to make a difference in patient's lives. From our teams packing cartons to our teams shipping to your door, we're all-in and here to support you. And, as a leading global distributing exporter, we offer reliable delivery options as well as business resources to get you the Covid-19 supplies you need. We delivery when others can't...
Vaccine Distribution Updates
Product availability & allocation
Global demand is outpacing supply for some personal protective equipment (PPE) and related products due to the coronavirus outbreak. This increased demand has caused shortages for some PPE and related products. We are allocating supply to customers with previous purchase history of these items. Search results and product pages will indicate which items in the catalog are on allocation.
We are working with government agencies and others in the industry to share information and address supply issues as they arise.
Testing methods for COVID-19 or SARS-CoV-2
There are two terms being used when discussing the coronavirus. COVID-19 is the coronavirus disease; SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the virus that causes the disease. They are often used interchangeably when we are talking about the pandemic or lab testing methods.
There are three types of lab testing methods/platforms available. They detect the virus or the patient’s response to the virus in different ways:
- Viral antigen
- Serology (antibody) tests
During the rise of viral RNA and viral antigen levels, a molecular (PCR or isothermal nucleic acid amplification based) or viral antigen test detects the presence of the virus. Often times, these molecular and viral antigen tests can be used as the primary basis for diagnosing your patient’s condition. Rather than going through the normal approval process, the U.S. Food and Drug Administration (FDA) is permitting all COVID-19 molecular and viral antigen tests to be cleared through its emergency use authorization (EUA) process during the pandemic. COVID-19 tests that go through the EUA process can request and secure a CLIA categorization.
Serology antibody tests detect the IgM and IgG antibodies that indicate your patient has developed an immune response to the virus but does not provide definitive evidence of a current infection. While experts say these tests will be important in the future, we have not seen widespread guidance on how these tests should be used. Serology antibody tests continue to be a focus in healthcare with the U.S. Food and Drug Administration (FDA) releasing very specific updates on these tests. The FDA has issued emergency use authorization (EUA) for some serology antibody tests. However, some serology antibody tests are being marketed without EUA. COVID-19 antibody serology tests without EUA currently default to a high complexity status. In addition, the accuracy and quality of those tests may vary greatly.
For more information visit FDA.gov and review the FDA’s Revised Policy on Antibody Tests and the FDA’s EUA Authorized Serology Test Performance page.
Lab testing options available from Rx Medical Warehouse SA
Which molecular tests are currently available?
A large number of manufacturers have received EUA for their molecular tests; the following are of potential importance to our customers. Each of these analyzers and tests are in high demand.
Please consult with your Rx Medical Warehouse Account Manager for details and or restrictions.
- Abbott Diagnostics (formerly Alere) ID NOW™
- QIAGEN QIAstat-Dx®
- Roche Cobas®
- Cepheid Xpert®
- Quidel Solana
- Mesa Biotech Accula™ (may be marketed as Sekisui Diagnostics)
Which viral antigen tests are currently available?
Rx Medical Warehouse has access to several suppliers with EUA authorizations.
Quidel is marketing its Sofia® SARS Antigen FIA, a rapid point-of-care antigen test to be used on the Sofia® Fluorescent Immunoassay Analyzer (“Sofia 1”) and the Sofia 2 Fluorescent Immunoassay Analyzer for SARS-CoV-2 in nasal or nasopharyngeal specimen. This is a “reader-style” test that identifies an active infection. Quidel is producing and getting tests to caregivers as fast as possible.
BD is marketing its Veritor™ SARS-CoV-2 chromatographic immunoassay test, a rapid point-of-care antigen test to be used on the BD Veritor Analyzer. This is a “reader-style” test that identifies an active infection. BD is producing and getting tests to caregivers as fast as possible.
AccessBio is marketing its CareStart™ COVID-19 antigen test. This is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal swab specimens either directly collected or collected in BD universal transport media from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of symptom onset.
On August 26, Abbott Diagnostics announced their BinaxNOW™ COVID-19 Ag Card rapid test for detection of COVID-19 infection. The test is highly portable (about the size of a credit card) and provides results in 15 minutes. BinaxNOW uses lateral flow technology, making it a familiar format for frequent mass testing through their healthcare provider. No equipment is required. On August 27, HHS announced an initiative to provide these tests initially to K-12 education; HHS has purchased the first 150 million tests and has rights to purchase additional tests. At this time, this test is now available through our distributor.
Each of these analyzers and tests are in high demand. Please consult with your Rx Medical Warehouse Account Manager for ability or restrictions
* Be advised that information contained herein is intended to serve as a useful reference for informational purposes only and is not complete clinical information. This information is intended for use only by competent healthcare professionals exercising judgment in providing care. Rx Medical Warehouse SA cannot be held responsible for any errors or omissions in the information.